NASDAQ · SBFMW
Healthcare · Drug Manufacturers - Specialty & Generic
$0.05
Up+$0.02 (+74.19%)
Updated Sep 20, 2026, 7:39 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 5 trading sessions · Daily adjusted prices
SBFMW closed at $0.05 after 5 trading sessions, up 33.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $0.0541 | $0.0541 | $0.054 | $0.054 | 2K |
| Sep 17, 2026 | $0.031 | $0.031 | $0.031 | $0.031 | 400 |
| Sep 14, 2026 | $0.031 | $0.031 | $0.031 | $0.031 | 298 |
| Aug 31, 2026 | $0.0311 | $0.0311 | $0.031 | $0.031 | 4.39K |
| Aug 25, 2026 | $0.031 | $0.0405 | $0.031 | $0.0405 | 1.65K |
The latest Smart Investors Daily articles mentioning SBFMW.
SBFMW research
Company profile and research snapshot.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Sep 16, 2026
The Company had previously published laboratory results on its library of Anti-Coronavirus compounds in August 2024 (J. 2024, 67, 13681−13702) and more recently in March 2026 (J.
Yahoo · Sep 16, 2026
Sunshine Biopharma Inc. (NASDAQ:SBFM) on Wednesday announced it advanced its lead Coronavirus drug candidate into IND-enabling studies. The company had previously published laboratory results on its library of compounds in August 2024 and more recently in March 2026. Background and Compound Research The company said that the nominated drug candidate for advanced development displayed nanomolar potency against the viral protease and had broad-spectrum activity against other SARS-CoV-2 variants of
Yahoo · Aug 31, 2026
FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.
Yahoo · Aug 26, 2026
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision OncologyNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is surprisingly straightforward: instead of giving the immune system a one-size-fits-all treatment, an mRNA vaccine can be designed to teach it what a particular tumor looks lik
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SBFMW.
No results
No recent SID articles mention SBFMW.
